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The Enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMG CoA reductase) catalyses conversion of 
HMG CoA to mevalonate during cholesterol biosynthesis. Lovastatin is used as an anti-cholesterol drug 
which blocks HMG CoA reductase activity. Lovastatin has been reported to be produced by Submerged 
Fermentation (SmF) and Solid State Fermentation (SSF) by fungi. Of-late it is used not only as anti-
cholesterol drug but as anti-inflammatory agent, cancer cell apoptosis, restoration of renal function, 
bone disorders treatment; immune-modulatory role is also being investigated. This review provides 
insight into the different lovastatin production strategies employed by SSF, its advantages over SmF, 
optimisation parameters, lovastatin genetics etc.  
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INTRODUCTION  
 
The World Health Organization estimated that 17.3 
million lives were lost in 2008 and an expected 23.6 
million people will die of cardiovascular diseases (CVD) 
by the year 2030 (WHO, 2011). Close to 80% of mortality 
rates were reported from the lower and middle income 
countries. Hypercholesterolemia is one of the reasons for 
these deaths. The treatment of the hypercholesterolemia 
is targeted by decreasing the low density lipoprotein 
(LDL) cholesterol and is best achieved by medications 
when diet and exercise fail (Lloyd-Jones et al.,2009) . A 
wide variety of biologically active compounds are 
produced by fungi, a large proportion of which are 
produced by the polyketide biosynthetic pathway. Fungal 
polyketides represent structurally diverse group and with 
many displaying important biological activities such as  
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antibiotic and other related pharmacological properties 
(Bedford et al., 1995). Noted among the fungal 
metabolites are statins (anti-cholesterol compounds) that 
are considered as the most important class produced by 
the polyketide pathway. Statins comprises of Compactin, 
lovastatin, pravastatin, simvastatin, rosuvastatin, 
atorvastatin and fluvastatin. Compactin and lovastatin are 
of biological origin whereas simvastatin, pravastatin, 
rosuvastatin etc are chemical modifications of compactin 
and lovastatin (Chakravarti and Sahai, 2004). The 
biosynthetic pathway involved in statin production starts 
from acetate units linked to each other in a head to- tail 
fashion to form a polyketide chain. Lovastatin (Figure 1) 
prevents formation of mevalonate from HMG Co-A 
(Sreenivasan et al., 2008; Marcin and Stanislaw, 2009) 
by competitively inhibiting the enzyme HMG CoA 
Reductase. Lovastatin can exist in two forms i.e hydroxyl 
from and lactone form, of which the hydroxyl-form is the 
active drug. The lactone forms (e.g. lovastatin, 
simvastatin, cerivastatin) are lipophilic while the acid  
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Figure 1. Structure of Lovastatin 
 
 
 
forms are hydrophilic for example atorvastatin, 
fluvastatin, pravastatin (Zamvil and Steinmann., 2002). 
Lovastatin is obtained from different genera and 
species of filamentous fungi. Several fungal genera 
including Aspergillus, Penicillium, Monascus, 
Paecilomyces, Trichoderma, Scopolariopsis, 
Doratomyces, Phoma, Phythium, Gymnoascus, 
Hypomyces and Pleurotus are reported as lovastatin 
producers (Bizukojc and Stanislaw, 2009, Cabral et al.,  
2010, Srinu et al., 2010). In addition even the 
Basidiomycetes mushrooms have been recently reported 
to be used. Pleurotus spp and its related strains produce 
higher concentrations of lovastatin (Alarcon et al., 2003). 
Recently, a marine actinomycete has also been reported 
to produce lovastatin (Srinu et al., 2010). This review 
gives an insight into lovastatin production by SSF in the 
last 5-6 years and the possible multiple (pleiotropic 
effects) applications of lovastatin in medical field.  
 
 
HISTORY 
 
A US based company (in 1950’s), Wm. S. Merrell Co., 
reported a compound with anti-cholesterol property, 
called as Triparanol (MER/ 29) which blocked the 
conversion of desmosterol to cholesterol. Later it was 
reported that triparanol was an ineffective drug and 
associated with lens cataracts, hair loss in rats and dogs, 
also higher doses causes blindness in rats (Steilberg, 
2006). This led to ban on triparanol. Masao Kuroda and 
Akira Endo, supported by their team, at Sankyo Co. 
Tokyo, screened numerous fungi and discovered that 
Penicillium citrinum produced anti-cholesterol compound. 
This compound from P. citrinum was christened as 
ML236B (referred to as compactin). With several tests 
the carcinogenic effects of compactin came to light due to 
noted lymphomas in dogs treated with higher doses of 
compactin. This led to the said company to halt proposed 
clinical trials. Later, Merck, a competitor, reported the  
 
 
 
 
production of Mevinolin (Lovastatin) from Aspergillus 
terreus. It was later discovered that in fact what they 
referred to as lymphomas associated with compactin 
were actually the accumulation of reductase proteins in 
endoplasmic reticulum in response to statin therapy., 
Merck got the approval from Food and Drug 
Administration (FDA) in 1987 to release Mevinolin into 
the market. However, Akira Endo in 1989, reported that 
Monascus sp also produced reductase inhibitors and 
subsequently obtained a patent (Steilberg, 2006; Endo, 
2008). 
 
 
Pleiotropic Effects of Lovastatin 
 
The clinical applications of lovastatin have been well 
documented (Sreenivasan et al., 2008). It finds its 
possible applications for more medical uses such as 
reducing instances of peripheral vascular diseases, 
prevention of strokes, stabilization of artheromatous 
plaques, improved endothelial functions and prevention 
of thrombus formation (Tandon et al., 2005; Barrios and 
Miranda, 2010). 
 
 
Alzheimers Disease (AD): Amyloid plaque formation in 
brain is noted in patients with AD due to production of 
neurotoxic amyloid protein (produced by alternate 
processing of amyloid precursor protein). Animal and cell 
culture experiments reported decreased prevalence of 
AD on lovastatin treatment (Eckert et al., 2005). Human 
trials did not yield 100% results and further work needs to 
be warranted in the same area to attribute exact role of 
lovastatin (Eckert et al., 2005). 
 
 
Multiple Sclerosis (MS): Lovastatin supressed 
production of tumor necreosis factor- α(TNF-α) by 
Interferon-α (IFN-α). A decreased level of inflammatory 
response and protection of hosts cellular damage was 
noted. Lovastatin also inhibited major histocompatibiliy 
complex-II (MHC-II) upregulation in antigen presenting 
cells (APC’s). Atorvastatin prevented or reversed 
paralysis in murine experiemental autoimmune 
encephalitis (EAE) models thus indicating the 
immunomodulatory role of lovastatin (Zamvil and 
Steinmann, 2002). 
 
 
Bone Disorders: In murine models prolonged infusions 
or large doses of lovastatin stimulated bone formation 
both in-vivo and in-vitro (Sreenivasan et al., 2008). Pre-
clinical studies reported that nano particle delivery of 
lovastatin may fasten human bone fractures (Garrett et 
al., 2007). This positive effect may also aid in treatment  
  
 
 
 
of osteoporosis (Sreenivasan et al., 2008). 
 
 
Renal Protection: Glomerulonephritis associated kidney 
damage may be retarded by lovastatin treatment. This 
may be possibly due to down regulation of inflammatory 
cytokines and activity of GTPases Ras superfamily. The 
exact role of statins is yet to be elucidated (Buemi et al., 
2002). 
 
 
Cancer: Induction of apoptotic response in human acute 
myeloid leukemia (AML) cells was noted on lovastatin 
treatment (Xia et al.,2001). Inhibition of 
geranylgeranylation of target proteins is the mechanism 
of lovastatin-induced apoptosis in AML cells. The 
antiproliferative properties of lovastatin may be used as 
an effective anticancer drug (Tandon et al., 2005). The 
mechanism underlying lovastatin induced apoptosis of 
malignant cells remains unclear (Bonovas et al., 2006; 
Glynn et al., 2008). About 20 %– 55% reduction in site-
specific cancers (colorectal, breast, prostate, lung and 
pancreatic) was observed with the use of statin therapy 
(Glynn et al., 2008). Inhibition of Ras farsenylation is 
associated with reduction and proliferation of cancer in 
human glioblastoma cells (Xia et al., 2001). Further 
studies need to be carried out to exactly elucidate if 
statins can be used as anti-cancer drug as concordant 
results have not been obtained (Sreenivasan et al., 
2008). 
 
 
Rheumatoid Arthritis (RA): Immunomodulation and 
modified endothelial function by lovastatin may aid to 
decrease problems associated with RA (Sreenivasan et 
al., 2008). 
A recent report suggests the role of statins as an 
immuno-modulator in treatment of vitiligo (Sreenivasan et 
al., 2008)and its beneficial part in graft transplant is being 
investigated (Sreenivasan et al., 2008). With its multiple 
applications, statins in future may play a pivotal role in 
medico-pharmaceutical field (Tandon et al., 2005). 
 
 
Biosynthesis and Genetics of Lovastatin Production 
 
The lovastatin pathway initiates from assembly of acetate 
units in head to tail fashion to form the two polyketide 
chains i.e Lovastatin Nonkedtide Synthase (LNKS) and 
Lovastatin Diketide Synthase (LDKS) (Barrios et al., 
2010). The first chain is Monacolin J (assembled form 2 
acetate units and 9 methionine units) which is later 
attached to the second chain i.e 2 Methyl butryl CoA 
(assembled from 2 acetate units and 1 methionine unit) 
lovastatin. The genes involved are lov B, lov C, lov F and  
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lov D. The multifunctional Polyketide Synthase (PKS) 
system encodes the LNKS and LDKS in A terreus. LNKS 
is a gene product of lov B, interacts with lov C (a putative 
enoyl reductase) to form the dihydro monacolin L which is 
later converted to Monacolin J. The LDKS, gene product 
of lovF, interacts with lov D (transesterase enzyme) that 
catalyzes the attachment of the 2-methylbutyric acid to 
monacolin J to form the functional lovastatin (Manzoni 
and Rollini, 2002, Sreenivasan et al., 2008, Barrios and 
Miranda, 2010).  
In tandem to this works on gene mutation and cloning 
of lovastatin genes into other hosts have also been 
reported (Pfeifer and Khosla, 2001, Xie and Tang, 2007). 
The possibility of conversion of Monacolin J (MCJ) to 
simvastatin (a semisynthetic form of lovastatin) using lov 
D gene that has been transferred to E coli has been 
reported (Xie and Tang, 2007). The substrate used for 
the lov D was α-dimethylbutyryl-S-NAC (or α-
dimethylbutyryl-S-methylthioglycolate). However, this 
reaction resulted in poor product turnout (Xie and Tang, 
2007). Later, DMB-S-methyl mercaptopropionate (DMB-
S-MMP) was used as an alternative substrate. This 
replacement with a cheaper substrate gave a better 
simvastatin yield but the rate of conversion was low 
(<60%). Lastly, site directed mutagenesis of cysteine to 
alanine and aspargine yielded a double mutant of E coli  
with almost >99% transformation of MCJ to simvastatin to 
yield 18g/L in approximately 18 hrs (Barrios and Miranda, 
2010).  
 
 
Solid Substrate Fermentation for Lovastatin 
Production 
 
Lovastatin production and optimisation of fermentation 
parameters has been of great interest since its discovery 
(Kumar et al., 2000, Sayyad et al., 2007, Jaivel and 
Marimuthu, 2010b). Many efforts and trials have been 
performed to increase the titre (Ferron et al., 2005, Jaivel 
and Marimuthu, 2010a, Prabhakar et al., 2011). Initially, 
all production processes were carried in Submerged 
Fermentations (SmF) by varying conditions of its physico-
nutritional parameters. The submerged processes have 
not yielded constant results and higher yield and hence a 
shift towards to Solid State Fermentation (SSF) was 
gaining popularity for multiple industrially important 
products such as enzymes, pigments, antibiotics etc. 
SSF has been widely employed in industrial productions 
because of its advantages such as better process control, 
maximum substrate utilisation, lower chances of 
contamination, easy downstream processing etc (Pandey 
et al., 2001). Many bacteria and fungi have been utilised 
for production of industrially important products by SSF 
(Pandey et al., 2001)  
The production of lovastatin by SmF has given varied 
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Table 1. Lovastatin Production by SmF 
 
Sl No. Microorganism 
Lovastatin yield 
(mg/L) 
References 
1 Aspergillus terreus 0.40 Szakacs et al., 1998  
2 Aspergillus terreus 2200 Kumar et al., 2000 
3 Aspergillus terreus 55 Samiee et al., 2003 
4 Monascus pilosus 725 Miyake et al., 2006  
5 Monascus purpureus 0.318 Sayyad et al., 2007  
6 Monascus purpureus 737 Ahmed et al., 2009  
 
 
 
results in terms of yield (Table 1). The selection of carbon 
and nitrogen source in the growth medium governs the 
lovastatin yield. Various nutritional combinations have 
been reported in submerged conditions (Sayyad et al., 
2007, Sorrentino et al., 2010, Osman et al., 2011,). 
Glucose, lactose, fructose and glycerol have been widely 
used as carbon source. Glucose and lactose are suited 
as good carbon source at low concentrations. Higher 
glucose concentration facilitates filamentous growth but 
decreases titre along with production of ethanol as by-
product and increasing medium viscosity (Bizukojc and 
Stanislaw, 2009). So a slowly metabolizable carbon 
source like lactose is best suited. Glycerol is also of 
choice (Miyake et al., 2006). Dox medium or modified dox 
medium also favours lovastatin growth (Atalla et al., 
2008). 
Various nitrogen sources often used in organic form 
(peptone, soyabean, corn steep liquor) and inorganic 
form (ammonium sulphate, ammonium chloride) (Sayyad 
et al., 2007; Atalla et al., 2008) also determine the final 
yield.  
Vis-a-vis there has been use of varied combinations of 
carbon: nitrogen sources with different organisms for 
study. Each organism utilizes C:N in varying amounts 
thus leading to varied results (Sayyad et al., 2007, 
Sorrentino et al., 2010, Osman et al., 2011).  
The addition of supplements to growth medium 
influences the yield too. Linoleic acid, butyrolactone, 
dodecane, acetic acid favours a higher yield. These 
supplements work best at low concentrations and work 
either directly incorporating themselves into specific 
pathway or by acting as an enzyme activator (Sorrentino 
et al., 2010 and Osman et al ., 2011). Butyrolactone and 
Dodecane (2.5%) increased the yield by 3-4 fold 
(Bizukojc and Stanislaw, 2009). Sodium acetate 
supplementation triggers better yield by acting as a 
precursor for statin synthesis (Osman et al., 2011). 
Lovastatin production also has been carried by SSF 
approaches with promising results. The results were far 
surprising that expected with high titre of 1110μg/gm dry 
weight of substrate, thus portraying immense potentials 
of SSF over SmF.  Numerous data is present regarding 
lovastatin production by SmF and optimisation 
parameters reported. The production of lovastatin by 
solid state fermentation (SSF) has gained popularity as it 
involves lower media cost, stability of the product, 
increased yield and better substrate porosity (Chanakya 
et al., 2011; Reddy et al., 2011). 
The substrates used in fermentation include wheat 
bran, rice bran, non-glutinous rice, orange peels, grain 
husks (Reddy et al., 2011; Jaivel and Marimuthu, 2010a; 
Chankya etal., 2011). Wheat bran topped the list as the 
best substrate, with a maximum yield of 3273.4 μg/g 
(Panasuriya and Singhal., 2010)  and a yield range of 
806 mg/L to 982.3 mg/L (Jaivel and Marimuthu, 2010a). 
Per se, an  increase or decrease in moisture content 
affects the oxygen and water balance (Panasuriya and 
Singhal., 2010) and decreases lovastatin yield. The 
higher yield associated with SSF is primarily due to 
increased mycelial density provided with an optimum 
moisture range between 60%-70% (Prabhakar et al., 
2011). Lovastatin yield of 730 μg/g of dry weight 
substrate i.e wheat bran at a moisture level of 65% and 
temperature of 30 
O
C has been reported using mutated 
strain of A terreus (Prabhakar et al., 2011). Rice bran 
was of good choice specially when supplemented with 
nitrogen source (as rice is poor in nitrogen source) and 
better compared to rice husk (Pie-Lien et al., 2007). Low 
protein content may be dealt by addition of peptone in 
substrate. Rice based unsupplemented medium yields 
1.703 mg/g lovastatin using Monascus purpureus MTCC 
369. Rice supplemented with soya bean powder, sucrose 
and yeast extract inoculated with M. ruber also resulted in 
high titre (Xu et al., 2005). 
Selection of glucose (repressive) along with non-
repressive carbon source in combination yields increased 
lovastatin titre in M. pilosus. Glucose and maltose are the 
best known carbon sources (444 mg/L). Glucose is said 
purported to exert repressive action but a combination of 
glucose, glycerol and peptone in medium is best for M. 
pilosus to produce lovastatin (Miyake et al., 2006). 
Dextrose, KH2PO 4 and FeSO4 do not aid much in  
  
 
 
 
lovastatin production when compared to NH4Cl, MgSO4 
and NaCl when present in medium inoculated with M. 
purpureus 369 (Panda et al, 2009b). Various physico-
nutritional parameters that govern lovastatin production 
have been well documented (Sayyad et al., 2007, Marcin 
and Stanislaw, 2009, Sorrentino et al., 2010, Osman et 
al., 2011). 
Presence of one amino acid is mandatory in the growth 
media. Riboflavin, pyridoxine and calcium pantothenate 
when used as supplements invariably increased yield, 
except for thiamine. Methionine is suited as it is directly 
involved in biosynthetic pathway and gives a yield of 180 
μg/ml (Marcin and Stanislaw, 2009). It is necessary to 
maintain a striking balance between carbon and nitrogen 
source for obtaining a desirable  lovastatin production as 
they regulate the biomass and metabolite production 
(Osman et al., 2011).  
Incorporation of various supplements to the growth 
medium has been studied (Marcin and Stanislaw, 2009) . 
Addition of tween-80 increases the yield  whereas ZnSO4 
had no effect on yield, but MgSO4 decreased yield by 
4.11% (Danuri, 2008). Addition of acetic aci at range of 
0.1% -0.3% also favoured good yield. Glycerol (3%), 
NaNO3 (0.2%) contributed in higher yield. A glycerol level 
above 0.3% decreased titre as it affected fungal cell 
perme-ability (Xu et al., 2005).  
The use of agro-based wastes (wheat bran, corn hull 
and rice husk), fruit wastes (sugarcane bagasse, orange 
peel and orange pulp) and their combination has been 
studied (Prahbakar et al., 2011, Reddy et al., 2011, 
Panasuriya and Singhal., 2010]. Addition of nutrient 
medium to dried substrate has also been the subject of 
study with contradictory results. Lower yield of lovastatin 
is noted when glucose, lactose, sucrose was 
incorporated into solid substrate (Panasuriya and 
Singhal, 2010). Glucose, lactose and sucrose when 
added to Dried Fermented Matter (DFM) tend to 
decrease the yield of lovastatin to 2101±51, 2534±29 and 
2435±38 μg g
-
 respectively. However, contradictorily a 
higher yield was recorded when sweet sorghum syrup is 
incorporated with nutrient solution (Jaivel and Marimuthu, 
2010a). 
Mutation by Ethyl Methyl Sulphonate (EMS) and UV of 
A terreus KLV28mu21 recorded higher yield (Prabhakar 
et al., 2011). A terreus isolated from contaminated oyster 
mushroom bed subjected to EMS and UV mutation 
(strains JPM-EMS2and JPM-UV2) produced lovastatin in 
better appreciable quantity (948.50mg/L and 1553.02 
mg/L) (Jaivel and Marimuthu, 2010a).  
Response Surface Methodology (RSM) approach has 
been well adopted to assess lovastatin yield and 
determine the optimum fermentation parameters (Sayyad 
et al., 2007). A temperature of 29.46
O
C, fermentation 
time of 14.43 days with an initial in-oculum level of 5 ml at 
pH 6.00 yields 3.432 mg/g (Panda et al., 2009a) of  
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lovastatin using M purpureus MTCC 369 under SSF. 
Fermentation studies have been revealed the 
temperature range of 28
O
C -30
O
C as the best suited 
temperature and at a pH range between 5-6, while for A 
fischerii its relative humidity is of 60%, pH 5, and 
temperature set at 30
0
C with lactose and malt extract as 
its main optimum is best suited for a maximum yield 
(Chanakya et al. ,2011). SSF holds true potential for 
production of many industrially important products 
(Pandey et al., 2001). The limitations that may be 
encountered in SSF are in controlling of process 
parameters and scale up from laboratory to exploitable 
industrial level (Mienda et al., 2011).  
The higher lovastatin production in SSF is primarily 
related to enhanced transcriptional rates of biosynthetic 
genes lov E and lov F resulting in yield increase by 4.6 
fold and 2 fold respectively.  The lov E and lov F 
transcrips accumulation was 20 and 6 fold lower than in 
SSF when a liquid medium (SmF) of identical 
concentration when used. Genetically engineered A 
terreus could synthesise 2,2 dimethyl butyrate (side chain 
of simvastatin) and produce simvastatin directly rather 
than lovastatin (Barrios-González et al., 2008). By 
isolating DNA, RNA and analysing them by 
corresponding blotting techniques it was confirmed that 
during SSF the gene transcript levels of lov genes (lov B 
and lov F) was higher when compared to SmF meanwhile 
the expression of gldB (NADP dependent glycerol 
dehydrogenase), gene for osmotolerance, in SSF seem 
to indicate the role of osmotic genes in A nidulans when 
inert substrate polyurethane foam was used (Barrios-
González et al., 2008). This study putatively 
substantiates the usage of SSF as a modern optimum 
technological approach for lovastatin production. 
 
 
CONCLUSION 
 
Lovastatin production has gained large scale importance 
with more emphasis on use of SSF approach. This has 
resulted in continual search for novel and cheaper 
substrates with stress on optimisation of production 
technology. The molecular level studies also substantiate 
the role of using SSF technology. With the pleiotropic 
effects unfolding, statins may be a master key to control 
or regulate many major diseases in the future 
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